Clinical trial
Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Severe Chronic Neutropenia
NCT00909584 is registered in ClinicalTrials.gov with Telik as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Randomized Study of Ezatiostat Hydrochloride (Telintra™, TLK199 Tablets) for Treatment of Severe Chronic Neutropenia
- Lead sponsor
- Telik
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 30, 2009
- Completion date
- May 31, 2013
- Enrollment
- 9 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
severe chronic neutropenia